Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 16NIH 2INDUSTRY 2NETWORK 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 2

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Laparotomy × Clear all
NCT02317705 2022-06-21

Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer

On Target Laboratories, LLC

Phase 2 Completed
48 enrolled 10 charts
Gynecologic

Ovarian Neoplasms

NCT03180307 2022-02-04

OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

On Target Laboratories, LLC

Phase 3 Completed
140 enrolled 11 charts 1 FDA
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡